The changes of intercellular spaces after proton pump inhibitor treatment in patients with erosive reflux disease

A prospective single center investigator initiated trial to evaluate the changes of intercellular spaces after proton pump inhibitor treatment in patients with erosive reflux disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0006504

Enrollment

Registered

2021-08-26

Start date

2021-08-31

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : As a single group, Retopra tablet (S-Pantoprazole) 20mg, by oral use once a day before breakfast, for a total of 4 weeks, and 4 weeks after initial & PPI drug administration, upper gastrointest

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Those who have been diagnosed with erosive reflux esophagitis and are over the age of 19 who are scheduled to undergo esophageal resection, and are under 75 years of age 2) Those who have had erosive reflux esophagitis LA-Aor above on EGD within the last 1 year 3) Those who have symptome of heartburn or acid regurgitation 4) Those who have been informed and consented to this study

Exclusion criteria

Exclusion criteria: 1) Non erosive reflux esophagitis 2) Barrett`s esophagus >2cm 3) Esophageal varix 4) Those who have coagulopathy (Platelet 3.0 × upper limit of normal (ULN) of the study site

Design outcomes

Primary

Measure	Time frame
Changes in the dilated intercellular spaces after 4 weeks of proton pump inhibitor administration compared to baseline	—

Secondary

Measure	Time frame
Changes in the scores of GERD-Q & GERD-HRQL after 4 weeks of proton pump inhibitor administration compared to baseline;Changes of mucosal erosions on endoscopy after 4 weeks of proton pump inhibitor administration compared to baseline;Changes of histologic findings after 4 weeks of proton pump inhibitor administration compared to baseline	—

Countries

Korea, Republic of

Contacts

Public ContactGa Hee Kim

Asan Medical Center

smallgh@hanmail.net+82-2-3010-5808

Outcome results